Uterine fibroids are noncancerous growths of the uterine muscle that affect the majority of women by age 50, though many have no symptoms. When symptoms occur — including heavy menstrual bleeding, pelvic pressure, and pain — they can significantly affect quality of life, fertility, and are the leading cause of hysterectomy in the United States. Treatment options have historically been limited to surgery, but medical options are rapidly expanding.
What's actually going on in research
GnRH receptor antagonists including elagolix and relugolix combination therapies are now approved to manage heavy fibroid bleeding, providing hormone suppression without the hypoestrogenic side effects of older GnRH agonists. Uterine fibroid embolization and newer non-surgical ablation techniques continue to be refined. Trials are exploring selective progesterone receptor modulators and other hormonally targeted drugs to shrink fibroids and preserve fertility, as progesterone signaling is central to fibroid growth.
GnRH antagonist combinations
Combination GnRH antagonist regimens with add-back estrogen and progestin — such as relugolix combination therapy — are now approved and reduce heavy bleeding while preserving bone density.
Selective progesterone receptor modulators
SPRMs are being studied to reduce fibroid volume and bleeding without full estrogen suppression, potentially offering a fertility-preserving medical option for women who wish to conceive.
Non-surgical ablation
MRI-guided focused ultrasound and radiofrequency ablation techniques are being refined in trials to safely destroy fibroid tissue with minimal recovery time and preservation of the uterus.
What to know before you search
Eligibility is based on fibroid burden, symptom severity, desire for fertility preservation, and prior treatment history.
What types of trials are currently open
- Medical therapy trials — Testing GnRH antagonists, SPRMs, and other hormonal agents to reduce fibroid bleeding and bulk.
- Fertility preservation trials — Evaluating treatments that shrink fibroids while maintaining or improving chances of conception.
- Minimally invasive procedure trials — Comparing focused ultrasound, radiofrequency ablation, and embolization for symptom relief.
- Recurrence prevention studies — Investigating whether hormonal therapy after myomectomy reduces fibroid recurrence rates.
- Quality-of-life studies — Measuring how fibroid treatments affect menstrual health, pain, and daily functioning.
Recently added Uterine Fibroids trials
FATIMA Trial: EGCG and Vitamin D3 for Prevention of Fibroid Recurrence
The aim of this randomized controlled clinical trial is to evaluate the efficacy of green tea (EGCG) and vitamin D3 supplementation in preventing uterine fibroid recurrence following fibroid removal.
Receive surgery using one of two techniques to reduce blood loss
The goal of this clinical trial is to compare two surgical techniques for reducing blood loss during transabdominal myomectomy in women with symptomatic uterine fibroids. The main question it aims to answer is whether bilateral uterine artery ligation reduces intraoperative blood loss more effectively than pericervical mechanical tourniquet application, without increasing operative complications. Researchers will compare bilateral uterine artery ligation with pericervical mechanical tourniquet application during open myomectomy to evaluate blood loss and surgical safety. Participants will undergo elective transabdominal myomectomy and will be randomly assigned to one of the two vascular control techniques before myoma enucleation.
Find Uterine Fibroids trials matched specifically to you
Answer 3 quick questions and we'll show you trials that fit your situation.